- Trials with a EudraCT protocol (27,979)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2,241)
27,979 result(s) found for: SAFETY.
Displaying page 534 of 1,399.
EudraCT Number: 2014-004925-42 | Sponsor Protocol Number: P04824 | Start Date*: 2015-04-13 |
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | ||
Full Title: Efficacy and Safety of 200 mcg BID Mometasone Furoate Nasal Spray (MFNS) vs Placebo as Adjunctive Treatment to Antibiotics in Relief of Symptoms of Acute Bacterial Sinusitis | ||
Medical condition: Acute Bacterial Sinusitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-003345-29 | Sponsor Protocol Number: 3568 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Kings College Hospital NHS Foundation Trust | |||||||||||||
Full Title: Safety of tenofovir alafenamide (TAF) in patients with a history of tubulopathy on tenofovir disoproxil fumarate (TDF) | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003972-42 | Sponsor Protocol Number: A1281198 | Start Date*: 2020-08-21 | |||||||||||
Sponsor Name:Pfizer, Inc. | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, FOUR-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY TRIAL OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPO... | |||||||||||||
Medical condition: Bipolar Disorder | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000061-37 | Sponsor Protocol Number: PR-002 | Start Date*: 2008-04-02 | |||||||||||
Sponsor Name:EURAND SPA | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of two doses of Zentase (EUR-1008) in Chronic Pancreatitis (CP) patients with Exocrine Pancreati... | |||||||||||||
Medical condition: Chronic Pancreatitis (CP) with Exocrine Pancreatic Insufficiency (EPI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003635-23 | Sponsor Protocol Number: XIG-AP 1 | Start Date*: 2008-08-14 | |||||||||||
Sponsor Name:Central Manchester and Manchester Children's Hospitals NHS Trust | |||||||||||||
Full Title: A PRELIMINARY EVALUATION OF THE SAFETY PROFILE OF TWENTY-FOUR HOUR INFUSION OF HUMAN RECOMBINANT ACTIVATED PROTEIN C (XIGRIS) EARLY IN SEVERE ACUTE PANCREATITIS. | |||||||||||||
Medical condition: Severe acute pancreatitis in man (with an APACHE II score of ≥ 15) appears to carry a considerably higher risk of death when compared to general critical care patients with similar APACHE II scores... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006488-22 | Sponsor Protocol Number: E2007-G000-227 | Start Date*: 2007-10-03 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy | |||||||||||||
Medical condition: Painful Diabetic Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006358-86 | Sponsor Protocol Number: ATG003-201 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:CoMentis, Inc., USA | |||||||||||||
Full Title: A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR ("WET") AGE-REL... | |||||||||||||
Medical condition: Neovascular ("wet") Age-related Macular Degeneration (NV- AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-007769-21 | Sponsor Protocol Number: H9D-SB-ITAE | Start Date*: 2009-09-11 | |||||||||||
Sponsor Name:Lilly Deutschland GmbH | |||||||||||||
Full Title: A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults with Type 1 Diabetes: Novel Pen with Memory Function (HumaPen® Memoir) v... | |||||||||||||
Medical condition: Pts with type 1 diabetes mellitus based on the WHO criteria, at least 8 years old, used an insulin pen device to inject at least 4 insulin doses/day for at least 2 months prior to the study and cur... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006902-27 | Sponsor Protocol Number: ALN-RSV01-105 | Start Date*: 2007-04-18 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and efficacy of intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with R... | |||||||||||||
Medical condition: Experimentally induced Respiratory Syncytial Virus infection. The experimental infectious dose has been titrated in a previous study in healthy volunteers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-003529-26 | Sponsor Protocol Number: 0431-073 | Start Date*: 2008-01-18 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and End-Stage Renal Disease Who Are on Di... | |||||||||||||
Medical condition: Type II Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005113-21 | Sponsor Protocol Number: RDEA806-202 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:Ardea Biosciences, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-001036-23 | Sponsor Protocol Number: CASM981C2442 | Start Date*: 2004-11-05 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A 12-week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of El... | ||
Medical condition: atopic dermatitis (atopic eczema) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004958-63 | Sponsor Protocol Number: CFTY720 0125E1 | Start Date*: 2005-08-04 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A two-year extension to a one-year, multicenter, partially blinded, double-dummy, randomized study to evaluate the efficacy and safety of FTY720 combined with reduced-dose or full-dose Neoral and c... | |||||||||||||
Medical condition: Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005215-98 | Sponsor Protocol Number: IUWP2005.01 | Start Date*: 2007-03-12 | |||||||||||
Sponsor Name:Sanquin Plasma Products | |||||||||||||
Full Title: Treatment in patients with recurrent infections and IgG Subclass Deficiency, and/or Deficient Anti-Polysaccharide Antibody Response. | |||||||||||||
Medical condition: Established diagnosis of IgG subclass deficiency, and/or (selective) antipolysaccharide antibody deficiency. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005956-34 | Sponsor Protocol Number: 0822-011 | Start Date*: 2007-03-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Ltd | |||||||||||||
Full Title: A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis | |||||||||||||
Medical condition: Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000558-22 | Sponsor Protocol Number: P02538 | Start Date*: 2005-06-20 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Assessment of the safety, efficacy, tolerability and pharmacokinetics of PegIntron plus Rebetol in pediatric patients with chronic hepatitis C. | |||||||||||||
Medical condition: Chronic Hepatitis C in pediatric patients. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003436-21 | Sponsor Protocol Number: D2450174 | Start Date*: 2005-10-26 | |||||||||||
Sponsor Name:Dainippon Sumitomo Pharma Europe Ltd | |||||||||||||
Full Title: A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (D... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011008-43 | Sponsor Protocol Number: CRAD001AIT16 - EVERHEART | Start Date*: 2009-06-24 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: Early vs.delayed EVERolimus in de novo HEART transplant recipients: optimozation of the safety/efficacy profile (EVERHEART Study) | |||||||||||||
Medical condition: de novo heart transplant patients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013395-48 | Sponsor Protocol Number: 1222.27 | Start Date*: 2009-11-04 | |||||||||||
Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo- and Active-Controlled, Incomplete Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Once Daily Treatment of 4 Doses of BI 1744 CL Inhalati... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) SI (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014286-20 | Sponsor Protocol Number: AGTC-AAT-002 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Applied Genetic Technologies Corporation | |||||||||||||
Full Title: A Multiple-Site, Phase 2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Alpha 1 Antitrypsin (rAAV1-CB-hAAT) in Patients with Alpha 1 Antitrypsin Deficiency | |||||||||||||
Medical condition: Alpha 1 antitrypsin deficiency.This is an inherited, genetic condition characterized by reduced serum levels of alpha-1 antitrypsin (AAT) which increases the risk of developing emphysema and liver ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
